Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Reported in EU/mg of peptide on the Certificate of Analysis, the reading is held to cell-culture-reference acceptance limits, supporting use of BPC-157 in fibroblast, endothelial, and mucosal-cell workflows where LPS-driven cytokine release would otherwise compromise the readout
Clinical trials have shown that patients using semaglutide lose an average of 14.9% of their body weight over 68 weeks
The compound is provided as a research reagent only
The average 12-month share price target was $24.7 per share, marking a potential 13.5% drop
US$ 27.02
US$ 22.69
US$ 24.11
US$ 24.66
-1775582746855.png&w=3840&q=75)
US$ 25.03
